AXA Private Equity acquires shareholdings of Riemser’s founding family and other minority stakeholders.
On August 21, Willkie client AXA Private Equity, the leading European diversified private equity firm, announced it has acquired Riemser Arzneimittel AG, an international specialty pharmaceutical company. AXA Private Equity has acquired the shareholdings of Riemser’s founding family and other minority stakeholders, including TVM Capital. Completion of the transaction is subject to approval by the German competition authority. Headquartered in Greifswald, Germany, Riemser focuses on the sale, marketing and lifecycle management of pharmaceutical products for niche therapeutic markets with high medical need in the fields of oncology, anti-infectives and dermatology.
Last month, Willkie assisted AXA Private Equity in the sale of a majority stake in Home Shopping Europe (HSE24). The Willkie team handing the current deal was led by partner Dr. Andreas Hautkappe and included partners Mario Schmidt, Dr. Stefan Joergens and Georg Linde; national partners Jan Wilms, Rolf Huenermann and Dr. Christian Rolf; and associates Dr. Octávio de Sousa, Mario Bammann, Johannes Eckhardt, Tobias Daubert, Christina Mann, Wolfgang Münchow, Jochen Riechwald, Dr. Stephanie Schmidt-Ehemann, Patrick Wacker and Daniel Zakrzewski.